Volume 15, Issue 1 (April-May 2012)
J Arak Uni Med Sci 2012, 15(1): 18-26 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bijani B, Charkhchian M, Asefzadeh M, Asefzadeh S, Moharramkhani H, Mahrma M. Comparison of the efficacy of hepatitis B vaccination by different routes of immunization. J Arak Uni Med Sci 2012; 15 (1) :18-26
URL: http://jams.arakmu.ac.ir/article-1-1051-en.html
URL: http://jams.arakmu.ac.ir/article-1-1051-en.html
Behzad Bijani1 
, Maliheh Charkhchian2 , Mina Asefzadeh2 , Saeed Asefzadeh2 , Halimeh Moharramkhani2 , Manoochehr Mahrma2
, Maliheh Charkhchian2 , Mina Asefzadeh2 , Saeed Asefzadeh2 , Halimeh Moharramkhani2 , Manoochehr Mahrma2
1- Qazvin University of Medical Sciences , Dr.Bijani@gmail.com
2- Qazvin University of Medical Sciences
2- Qazvin University of Medical Sciences
Abstract: (11215 Views)
Background: Low immunogenicity of hepatitis B vaccine is an important problem in patients with chronic renal failure (CRF). A possible solution is intradermal versus conventional intramuscular delivery of vaccine in this population. The goal of this study was to compare the efficacy of these routes of vaccination in Bu-alicina Dialysis Center, Qazvin, Iran.
Materials and Methods: This randomized clinical trial was done on 29 CRF non-responders randomly allocated to two groups. Fifteen patients received 40 μg of euvax B vaccine intradermally and 14 patients received 160 μg of this vaccine intramuscularly. Anti-HBs antibody titre was measured after 1, 6, and 12 months. Seroprotection was defined as anti-HBs antibody titre above 10 lU/L. Data were analyzed using SPSS software version 16.
Results: Difference of seroprotection rate between two groups was not statistically significant after1and 6 months however, after 12 months, seroprotection rate was 93.3% in the interadermal group versus 50% in the intramuscular group (p<0.05).
Conclusion: Considering the high cost of vaccination, intradermal vaccination may be a reasonable choice in CRF patients.
Subject:
Infection
Received: 2011/02/12
Received: 2011/02/12
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
